A Randomized Controlled Trial of Sublingual Sufentanil in Early Management of Pain in Trauma
Authors' conclusion
In this cohort of trauma patients with moderate to severe pain, the VNRS at 30 minutes after administration of analgesics did not differ between sublingual sufentanil and standard care.
Study context
- Population
- Adult trauma patients (18 to 70) in the ED with VNRS (0–100) ≥50, level-1 trauma centres of the Linking Investigator in Trauma and Emergency Services (LITES) network
- Participants
- 150 patients
- Comparison
- Sublingual sufentanil vs standard care
- Primary endpoint
- VNRS for clinical pain measurement (0-100)
- Follow-up
- 30 minutes after treatment
Methodological detailsprospective, multicentre, open-label, 1:1 randomisation, Enrolment July 2022 to January 2024
- Prospective
- Multicentre
- Open-label
- 1:1 randomisation
- Enrolment July 2022 to January 2024
Primary result
As reported in the abstract
VNRS (0-100) · 30 minutes
Sufentanil
66
SD 23
Standard care
68
SD 27
P = 0.37
Secondary outcomes
| Outcome | P value |
|---|---|
| Health care Professional Global Assessment (HPGA) · 30 minutesMore patients scored good or excellent with standard care | P = 0.009 |
Health care Professional Global Assessment (HPGA) · 30 minutes
- Decreased pain scores in the standard care group vs sufentanil
Safety
Nausea, vomiting, headache, dizziness, hypoxia, hypotension, need for advanced airway
- No difference in incidence
Original publication
A Randomized Controlled Trial of Sublingual Sufentanil in Early Management of Pain in Trauma. Anesth Analg. Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →